COVID-19–induced atypical pulmonary lymphocytes

A 39-year-old man treated for a T-cell/histiocyte-rich large B-cell lymphoma–like transformation of nodular lymphocyte-predominant Hodgkin lymphoma with an aggressive and diffuse clinical presentation was hospitalized for fever and aplasia after the fourth cycle of rituximab plus doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone. Results of the polymerase chain reaction test routinely performed in the context of pandemic COVID-19 were positive. Initially, there were no severe pulmonary symptoms, and the computed tomography scan showed moderate lung damage. Because persistence of lymphoma was proven based on results of the axillary lymph node biopsy, second-line rituximab, dexamethasone, cytarabine, and cisplatin treatment was initiated.